Octapharma
Clinical trials sponsored by Octapharma, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot could help Immune-Compromised patients fight infections Results expected Sep 2026 (estimated)
- New drug aims to stop swelling attacks in hereditary angioedema Results expected Dec 2026 (estimated)
- New hope for rare clotting disorder: drug aims to prevent dangerous clots during surgery and delivery Results expected Dec 2026 (estimated)
- New study tests clotting drug for safer surgery in women with hemophilia a Results expected Feb 2027 (estimated)
-
Head-to-Head safety check: which Clot-Reversal drug is safer before emergency surgery?
Disease control OngoingThis observational study compares the safety of two drugs, BALFAXAR and KCENTRA, used to reverse the effects of vitamin K antagonist blood thinners (like warfarin) in adults who need urgent surgery or an invasive procedure. The main goal is to see how often blood clots (thromboem…
Sponsor: Octapharma • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New shot could help Immune-Compromised patients fight infections
Disease control OngoingThis phase 3 trial is testing a new medicine called Newnorm, a concentrated antibody solution given as a shot under the skin, in 50 people with primary immunodeficiency (a condition where the immune system doesn't work properly). The goal is to see if Newnorm can prevent serious …
Phase 3 • Sponsor: Octapharma • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New clotting factor combo aims to tame von willebrand bleeding
Disease control OngoingThis study looks at how well Eqwilate, a concentrated mix of two clotting proteins (VWF and FVIII), controls bleeding in people with von Willebrand disease. It includes patients aged 6 and older who use Eqwilate on demand, before surgery, or as regular prevention. Researchers tra…
Sponsor: Octapharma • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC